

CROHN'S DISEASE AND ULCERATIVE COLITIS ENROLLMENT & PRESCRIPTION FORM PHONE: 800-641-8475 FAX: 800-530-8589 WFB: www.WellDyneSpecialty.com

WE	To subspecialty Pharmacy To Subspecialty Pharmacy	omit a new prescription via eRx, use this may not submit prescriptions via the may choose any pharmacy of the	e NPI 1902298805. Faxed fax and must submit origii	prescriptions will onl	y be accepted from	om prescribing pra			
PATIENT FORMATION	Patient: Caregiver:								
	DOB: Male	Female Weight: kgs o	or Ibs (check one) Heigh	t: in or	cm (check one)	Recorded Date: _		_	
	Best Phone #:	Cell Alternate Ph	one #:						
ĸ)	
	ICD-10 Code for requested ther	ару:	ICD-10 Code(s) for other medical conditions:						
	PLEASE FAX	COPY OF ALL INSURANCE C	ARDS (FRONT & BACK) INCLUDING ME	DICAL AND PR	RESCRIPTION			
MEDICAL ASSESSMENT	PRIOR HISTORY:	PRIOR BIOLOGIC USE: DAT	TE OF LAST DOSE:	DOSE: PRIOR (FAILED) T					
	5-ASA	Remicade®		Does the patient have an active infection? Yes N			No		
	Immunosuppressants	Humira®			Does the patient require injection training?				
	(6-MP or other)	Cimzia®		a Negative TB test	result? Yes	No			
	Corticosteroids	Other							
DIC	Methotrexate			Data of Toot:					
ME	Surgery			Date of Test:					
	Other								
		PLEASE PROVIDE ALL CLINICAL	. INFORMATION INCLUD	ING LAB RESULTS	ON ALL FORMS	5			
	MEDICATION	DOSE/STRENGTH	DIRECTI	ONS	QU	ANTITY	REFILL	s	
		Starter Dose: 6 x 40mg/0.8ml	160 mg Sub-Q Day 1, 80 Day 29 and every other		1 Kit = 6 x 40 mg Pens 3 Cartons = 6 x 40 mg PFS		0		
	Humira® (adalimumab) Enroll in Humira® Complete	Maintenance Dose: 40 mg Pens 40 mg Prefilled Syringes (PFS)	40 mg Sub-Q every oth	er week	1 Carton = 2 x 40 mg Pens 1 Carton = 2 x 40 mg PFS 2 Cartons = 4 x 40 mg Pens 2 Cartons = 4 x 40 mg PFS				
	Humira Citrate Free	Starter Dose: 3 x 80mg/0.8ml	160 mg Sub-Q Day 1, 80 mg Day 29 and every other we		1 Kit = 3 x 80 mg Pens		0		
	(adalimumab)	Maintenance Dose: 40 mg Pens 40 mg Prefilled Syringes (PFS)	40 mg Sub-Q every oth	er week	1 Carton = 2 x 40 mg Pens 1 Carton = 2 x 40 mg PFS				
	Entyvio® (vedolizumab)	200mg Cingle Hee Viel	Starter Dose: Infuse 300 mg intravenously over 30 minutes at week 0, 2, and 6		3 Vials		0		
NOI	Enroll in EntyvioConnect	300mg Single Use Vial	Maintenance Dose: Infuse 300 mg intravend minutes every 8 weeks	1 Vial					

PRESCRIPTION INFORMATI

·	40 mg Pens 40 mg Prefilled Syringes (PFS)	40 mg Sub-Q every other week	2 Cartons = 4 x 40 mg Pens 2 Cartons = 4 x 40 mg PFS	
Humira Citrate Free	Starter Dose: 3 x 80mg/0.8ml	160 mg Sub-Q Day 1, 80 mg Day 15, 40 mg Day 29 and every other week thereafter	1 Kit = 3 x 80 mg Pens	0
(adalimumab)	Maintenance Dose: 40 mg Pens 40 mg Prefilled Syringes (PFS)	40 mg Sub-Q every other week	1 Carton = 2 x 40 mg Pens 1 Carton = 2 x 40 mg PFS	
Entyvio® (vedolizumab)	000 0'	Starter Dose: Infuse 300 mg intravenously over 30 minutes at week 0, 2, and 6	3 Vials	0
Enroll in EntyvioConnect	300mg Single Use Vial	Maintenance Dose: Infuse 300 mg intravenously over 30 minutes every 8 weeks	1 Vial	
Stelara® (ustekinumab) Enroll in CarePath®	Starter Dose IV: 2 Vials of 130 mg/26 mL IV 3 Vials of 130 mg/26 mL IV 4 Vials of 130 mg/26 mL IV	55 kg or less – Infuse 260 mg single dose over at least 1 hour 56 kg to 85 kg – Infuse 390 mg single dose over at least 1 hour More than 85 kg – Infuse 520 mg single dose over at least 1 hour	Total amount of single use vials	0
	Maintenance Dose: 90 mg Prefilled Syringe	Inject 90 mg SQ 8 weeks after the initial IV starter dose then 90 mg every 8 weeks thereafter	90 mg Prefilled Syringe Qty:	
Remicade® (infliximab) Inflecra	100 mg Lyophilized Vials (LYO)	Starter Dose: 5 mg/kg IV at weeks 0, 2 and 6	Vial(s)	0
Renflexis Enroll in CarePath®	100 Hig Lyophilized Viais (LTO)	Maintenance Dose: 5 mg/kg IV every 8 weeks	Vial(s)	
Cimzia® (certolizumab) Enroll in Cimzia® Connect	Starter Dose: Cimzia Starter Kit (Prefilled Syringes) 200 mg Lyophilized Vials (LYO)	400 mg Sub-Q at weeks 0, 2, and 4	1 Kit = 6 x 200 mg/mL PFS 3 Cartons = 6 x 200 mg Vials (LYO)	0
Enroll III Ciliizia - Connect	Maintenance Dose: 200 mg/mL Prefilled Syringes 200 mg Lyophilized Vials (LYO)	400 mg Sub-Q every 4 weeks 200 mg Sub-Q every 2 weeks	1 Carton = 2 x 200 mg/mL PFS 1 Carton = 2 x 200 mg Vials (LYO)	
Simponi® (golimumab)	Starter Dose: 3 x 100mg/ml	Inject 200 mg SQ at week 0, then 100 mg at week 2	SmartJect Autoinjector® OR PFS	0
Enroll in Jansseen CarePath®	Maintenance Dose: 1 x 100mg/ml	Inject 100 mg SQ every 4 weeks	SmartJect Autoinjector® OR PFS	
Other				



Patient: ___

CROHN'S DISEASE AND ULCERATIVE COLITIS ENROLLMENT & PRESCRIPTION FORM

PHONE: 800-641-8475 **FAX**: 800-530-8589 **WEB**: www.WellDyneSpecialty.com

To submit a new prescription via eRx, use NPI 1902298805. Faxed prescriptions will only be accepted from prescribing practitioners. Patients may not submit prescriptions via fax and must submit original copies in person or via the mail. Prescribers are reminded patients may choose any pharmacy of their choice.

	INJECTION TRAINING: O			OFFICE TO COORDINATE WELLDYNE SPECIAL			TY TO COORDINATE			
,	Anticipated Start Date:		Prescriber Specialty:							
TIOI	Ship to:	Patient	Physician	Clinic	Other:					
RMA	Fax #:									
INFOF	Office Address:				City:		State:	Zip:		
<u>~</u>	The terms and conditions posted at www.WellDyneSpecialty.com have been read by the person signing this form and are incorporated into this document by reference.								ference.	
BER	The data privacy terms posted at www.WellDyneSpecialty.com have been read by the person signing this form and are incorporated into this document by reference.									
PRESCRI	I understand that WellDyne Specialty may transfer this prescription to another pharmacy as an agent of the prescriber if unable to dispense.									
RES	Prescriber's Name:			Prescriber's Signature:		Date:				
1	Use sub	stitution	Dispense as wr	itten						

_____ DOB: _____

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately by calling (800)-641-8475 to obtain instructions as to the proper destruction of the transmitted material.